Celiac disease is an autoimmune disease that occurs when indigestion of gluten damages the small intestine. Celiac disease often has a genetic predisposition
Albany, NewYork (PRWEB) February 27, 2015
The report analyzes the primary growth factors, market restraints, opportunities, and trends in the global celiac disease market. It also assesses key players in the industry, their financial outlook, research and development activities, and investments.
Celiac disease is an autoimmune disease that occurs when indigestion of gluten damages the small intestine. Celiac disease often has a genetic predisposition. According to analysts, about one in every 100 people is affected by celiac disease across the globe. When gluten, a protein found in barley, wheat, and rye, is not digested by the body, the immune system attacks the small intestine. This leads to damage of the tiny finger like projections lining the small intestine (villi) that assist in the absorption of nutrients. When the villi get damaged, the absorption of nutrients is reduced.
Statistics show that two and a half million Americans are at risk of complications arising out of undiagnosed celiac disease. The disease may occur any time after a person consumes foods that contain gluten. If the disease is not properly managed, it can lead to serious health complications such as Type I diabetes, multiple sclerosis (MS), dermatitis herpetiformis, osteoporosis, infertility, anemia, miscarriage, migraines, epilepsy, short stature, and intestinal cancers.
As there is no specific treatment for celiac disease, most patients have to rely on gluten-free diet plans for a long time. However, in some cases immune suppressants and steroids are prescribed by doctors to contain and manage the symptoms in severe cases. This accounts for about 5% of the total population of patients suffering from celiac disease. Unfortunately, there is no preventative medication or cure for this disease.
The future of the global celiac disease market is anticipating the introduction of Alba/Teva’s larazotide acetate in the U.S. and in the European Union in 2018 and 2019 respectively. The release of Alvine/AbbVie’s latiglutenase in the U.S. and in the European Union in 2019 and 2020 respectively is also anticipated, which is set to change the way this disease is managed. These drugs will also drive the global market for celiac disease. These drugs are targeted towards patients who are exposed to gluten food while living on a gluten-free diet. This number will account for about 95% of the total population of celiac disease patients.
All Latest Market Research Report @ http://www.researchmoz.us/latest-report.html
The report on the global celiac disease market states that the market will gain rapid growth with the introduction of these drugs. It also states that in the near future, unmet demand for medication and medical attention, reliable diagnoses, increasing awareness about gluten-free diet, lack of approved pharmacological therapies, improved compliance to a gluten-free diet, and better therapies for refractory celiac disease will prove to be great opportunities for key players in the global celiac disease market.
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis.We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports.We provide our services to all sizes of organizations and across all industry verticals and markets.Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
90 State Street, Suite 700
Albany, NY 12207
USA and Canada Toll Free: 866-997-4948